Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Maxcyte (MXCT) Gross Margin (2020 - 2025)

Maxcyte (MXCT) has disclosed Gross Margin for 6 consecutive years, with 119.31% as the latest value for Q4 2025.

  • Quarterly Gross Margin fell 19307.0% to 119.31% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 127.9% through Dec 2025, up 3198.0% year-over-year, with the annual reading at 127.9% for FY2025, 4628.0% up from the prior year.
  • Gross Margin for Q4 2025 was 119.31% at Maxcyte, down from 76.63% in the prior quarter.
  • The five-year high for Gross Margin was 177.99% in Q1 2024, with the low at 411.21% in Q4 2021.
  • Average Gross Margin over 5 years is 44.23%, with a median of 85.66% recorded in 2025.
  • The sharpest move saw Gross Margin plummeted -55910bps in 2021, then skyrocketed 45795bps in 2022.
  • Over 5 years, Gross Margin stood at 411.21% in 2021, then surged by 111bps to 46.74% in 2022, then crashed by -592bps to 230.04% in 2023, then skyrocketed by 132bps to 73.76% in 2024, then crashed by -262bps to 119.31% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 119.31%, 76.63%, and 82.14% for Q4 2025, Q3 2025, and Q2 2025 respectively.